Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGLE trial of durvalumab with or without tremelimumab versus standard of care in recurrent or metastatic squamous cell carcinoma of the head and neck
MOH_2017-06-12_000512Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Durvalumab monotherapy, Durvalumab + tremelimumab and Standard of care (3 arms). Primary endpoints: Overall survival for durvalumab + tremelimumab versus standard of care and Overall survival for durvalumab monotherapy versus standard of care. Started Oct 2015; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2017-06-12_000512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-12_000512.